Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.82), $1.08 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $44.91 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.